Pharmos
Corporation to Present at the BIO 2002 International Convention
& Exhibition
Presentation
on June 10 at 3:45 pm to be Webcast
ISELIN, N.J., June 7 /PRNewswire-FirstCall/ --
Pharmos Corporation (Nasdaq: PARS; Nasdaq Europe: PHRM)
announced today Dr. Gad Riesenfeld, President & COO,
will present at the Investor Forum of the BIO 2002 International
Convention & Exhibition in Toronto on Monday, June
10, at 3:45 p.m. Eastern Time. The presentation will outline
the Company's progress toward solidifying its position
in the therapeutic marketplace for neurological indications,
including the status of its pivotal trial of dexanabinol
for traumatic brain injury and important preclinical programs.
Organizers
from the Biotechnology Industry Organization (BIO), who
maintain the event is the world's largest annual biotechnology
conference, expect roughly 14,000 industry leaders, financial
contacts and media representatives from 50 different countries
to attend. A simultaneous webcast of Pharmos' presentation
will be accessible through the Investor Relations section
of Pharmos' website at http://www.pharmoscorp.com/ and
will be archived for a limited time afterwards.
Pharmos
discovers, develops, and commercializes novel therapeutics
to treat a range of neurological disorders such as traumatic
brain injury, stroke, pain, multiple sclerosis, and other
CNS and peripheral neuro-inflammatory indications.
Statements
made in this press release related to the business outlook
and future financial performance of the Company, to the
prospective market penetration of its drug products, to
the development and commercialization of the Company's
pipeline products and to the Company's expectations in
connection with any future event, condition, performance
or other matter, are forward looking and are made pursuant
to the safe harbor provisions of the Securities Litigation
Reform Act of 1995. Such statements involve risks and
uncertainties which may cause results to differ materially
from those set forth in these statements. Additional economic,
competitive, governmental, technological, marketing and
other factors identified in Pharmos' filings with the
Securities and Exchange Commission could affect such results.
back
to News Room
